Tocolysis with beta-adrenergic receptor agonists

Aaron Caughey, Julian T. Parer

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Beta-adrenergic receptor agonists have been used for tocolysis in the setting of preterm labor for more than three decades. One of these agents, ritodrine hydrochloride, is the only Federal Drug Administration (FDA) approved drug for the treatment of preterm labor. Despite their widespread use, only a few prospective randomized placebo-controlled trials have been performed. These agents have been shown to have more patients deliver beyond 48 hours after the onset of treatment as compared with controls, but have never shown a difference in neonatal outcomes. Because they are one of the few tocolytic agents to have been shown to make a difference when compared with controls, the beta-agonists are commonly used as the control groups in studies examining the efficacy of newer tocolytic agents. In general, agents such as nifedipine, magnesium sulfate, and atosiban have not been shown to be more efficacious than the beta-agonists. However, several studies have shown these agents to have less side effects and lower discontinuation rates than the beta-agonists.

Original languageEnglish (US)
Pages (from-to)248-255
Number of pages8
JournalSeminars in Perinatology
Volume25
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Tocolytic Agents
Tocolysis
Adrenergic beta-Agonists
Premature Obstetric Labor
Ritodrine
Magnesium Sulfate
Nifedipine
Pharmaceutical Preparations
Randomized Controlled Trials
Placebos
Control Groups
Therapeutics
atosiban

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Tocolysis with beta-adrenergic receptor agonists. / Caughey, Aaron; Parer, Julian T.

In: Seminars in Perinatology, Vol. 25, No. 4, 2001, p. 248-255.

Research output: Contribution to journalArticle

Caughey, Aaron ; Parer, Julian T. / Tocolysis with beta-adrenergic receptor agonists. In: Seminars in Perinatology. 2001 ; Vol. 25, No. 4. pp. 248-255.
@article{86911c96dfcb41929cf8b2ce07717635,
title = "Tocolysis with beta-adrenergic receptor agonists",
abstract = "Beta-adrenergic receptor agonists have been used for tocolysis in the setting of preterm labor for more than three decades. One of these agents, ritodrine hydrochloride, is the only Federal Drug Administration (FDA) approved drug for the treatment of preterm labor. Despite their widespread use, only a few prospective randomized placebo-controlled trials have been performed. These agents have been shown to have more patients deliver beyond 48 hours after the onset of treatment as compared with controls, but have never shown a difference in neonatal outcomes. Because they are one of the few tocolytic agents to have been shown to make a difference when compared with controls, the beta-agonists are commonly used as the control groups in studies examining the efficacy of newer tocolytic agents. In general, agents such as nifedipine, magnesium sulfate, and atosiban have not been shown to be more efficacious than the beta-agonists. However, several studies have shown these agents to have less side effects and lower discontinuation rates than the beta-agonists.",
author = "Aaron Caughey and Parer, {Julian T.}",
year = "2001",
language = "English (US)",
volume = "25",
pages = "248--255",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Tocolysis with beta-adrenergic receptor agonists

AU - Caughey, Aaron

AU - Parer, Julian T.

PY - 2001

Y1 - 2001

N2 - Beta-adrenergic receptor agonists have been used for tocolysis in the setting of preterm labor for more than three decades. One of these agents, ritodrine hydrochloride, is the only Federal Drug Administration (FDA) approved drug for the treatment of preterm labor. Despite their widespread use, only a few prospective randomized placebo-controlled trials have been performed. These agents have been shown to have more patients deliver beyond 48 hours after the onset of treatment as compared with controls, but have never shown a difference in neonatal outcomes. Because they are one of the few tocolytic agents to have been shown to make a difference when compared with controls, the beta-agonists are commonly used as the control groups in studies examining the efficacy of newer tocolytic agents. In general, agents such as nifedipine, magnesium sulfate, and atosiban have not been shown to be more efficacious than the beta-agonists. However, several studies have shown these agents to have less side effects and lower discontinuation rates than the beta-agonists.

AB - Beta-adrenergic receptor agonists have been used for tocolysis in the setting of preterm labor for more than three decades. One of these agents, ritodrine hydrochloride, is the only Federal Drug Administration (FDA) approved drug for the treatment of preterm labor. Despite their widespread use, only a few prospective randomized placebo-controlled trials have been performed. These agents have been shown to have more patients deliver beyond 48 hours after the onset of treatment as compared with controls, but have never shown a difference in neonatal outcomes. Because they are one of the few tocolytic agents to have been shown to make a difference when compared with controls, the beta-agonists are commonly used as the control groups in studies examining the efficacy of newer tocolytic agents. In general, agents such as nifedipine, magnesium sulfate, and atosiban have not been shown to be more efficacious than the beta-agonists. However, several studies have shown these agents to have less side effects and lower discontinuation rates than the beta-agonists.

UR - http://www.scopus.com/inward/record.url?scp=0034877632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034877632&partnerID=8YFLogxK

M3 - Article

C2 - 11561912

AN - SCOPUS:0034877632

VL - 25

SP - 248

EP - 255

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 4

ER -